Celltrion’s Remsima SC subcutaneous infliximab biosimilar produces “statistically greater improvements in clinical outcomes” for rheumatoid arthritis patients compared to intravenous infliximab, according to new data published by the Korean firm.
Publishing its findings at the latest European Alliance of Associations for Rheumatology (EULAR) congress, Celltrion revealed that “data from a new post-hoc analysis show a statistically significant difference in clinical outcomes with subcutaneous infliximab
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?